Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/117328
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Williams, James P. | - |
dc.contributor.author | Hurst, Jacob | - |
dc.contributor.author | Stöhr, Wolfgang | - |
dc.contributor.author | Robinson, Nicola | - |
dc.contributor.author | Brown, Helen | - |
dc.contributor.author | Fisher, Martin | - |
dc.contributor.author | Kinloch, Sabine | - |
dc.contributor.author | Cooper, David A. | - |
dc.contributor.author | Schechter, Mauro | - |
dc.contributor.author | Tambussi, Giuseppe | - |
dc.contributor.author | Fidler, Sarah | - |
dc.contributor.author | Carrington, Mary | - |
dc.contributor.author | Babiker, Abdel | - |
dc.contributor.author | Weber, Jonathan | - |
dc.contributor.author | Koelsch, Kersten K. | - |
dc.contributor.author | Kelleher, Anthony D. | - |
dc.contributor.author | Phillips, Rodney E. | - |
dc.contributor.author | Frater, John | - |
dc.contributor.author | Miró Meda, José M. | - |
dc.contributor.author | Gatell, José M. | - |
dc.contributor.author | SPARTAC Trial Investigators | - |
dc.date.accessioned | 2017-11-02T12:27:38Z | - |
dc.date.available | 2017-11-02T12:27:38Z | - |
dc.date.issued | 2014-09-12 | - |
dc.identifier.issn | 2050-084X | - |
dc.identifier.uri | http://hdl.handle.net/2445/117328 | - |
dc.description.abstract | In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | eLife Sciences | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.7554/eLife.03821 | - |
dc.relation.ispartof | eLife, 2014, vol. 3, p. e03821 | - |
dc.relation.uri | https://doi.org/10.7554/eLife.03821 | - |
dc.rights | cc-by (c) Williams, James P. et al., 2014 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Antiretrovirals | - |
dc.subject.classification | Malalties infeccioses | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.other | HIV (Viruses) | - |
dc.subject.other | Antiretroviral agents | - |
dc.subject.other | Communicable diseases | - |
dc.subject.other | Clinical trials | - |
dc.title | HIV-1 DNA predicts disease progression and post-treatment virological control | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 649160 | - |
dc.date.updated | 2017-11-02T12:27:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25217531 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
649160.pdf | 1.21 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License